2,000
Participants
Start Date
December 15, 2017
Primary Completion Date
December 29, 2023
Study Completion Date
December 29, 2023
VPM1002 (Recombinant BCG Vaccine)
"VPM1002 is a formulated, lyophilized cake of live recombinant Mycobacterium bovis rBCGÄureC::Hly+; VPM1002.~VPM1002 is the active pharmaceutical ingredient. It is a genetically modified BCG vaccine derived from the Mycobacterium bovis BCG subtype Prague characterized as rBCGÄureC::Hly+. Single dose of VPM1002 is administered intradermally."
Placebo
Single dose of Placebo is administered intradermally.
International Centre for Diarrhoeal Disease Research, Dhaka
Christian Medical College and Hospital, Ludhiana, Ludhiana
Government Medical College, Jammu, Jammu
B.J. Govt. Medical College and Sassoon General Hospitals, Pune
Mahatma Gandhi Institute of Medical Sciences, Sevagram, Sevāgrām
Mahavir Hospital & Research Centre, Hyderabad, Hyderabad
MV Hopsital for Diabetes Pvt Ltd, Chennai, Chennai
Sri Ramachandra Hospital Chennai, Chennai
Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry
Christian Medical College and Hospital, Vellore, Vellore
Serum Institute of India Pvt. Ltd.
INDUSTRY